| Development Project | Target | Indications | Modality | Country | Development stage | |||
|---|---|---|---|---|---|---|---|---|
| Nonclinical | Phase1 | Phase2/3 | Filed | |||||
| Nanvuranlat (Development code: JPH203) (Intravenous injection) |
LAT1
|
Biliary tract cancer
|
Low molecular
|
Japan
|
＊
|
|||
| Nanvuranlat (Development code: JPH203) (Intravenous injection) |
LAT1
|
Biliary tract cancer
|
Low molecular
|
US
|
＊＊
|
|||
| Nanvuranlat (Development code: JPH203) (Oral administration) |
LAT1
|
Biliary tract cancer
|
Low molecular
|
Japan and overseas
|
|
|||
| Nanvuranlat (Development code: JPH203) Companion diagnostic |
Non disclosure
|
Biliary tract cancer
|
Diagnostic
|
Japan
|
|
|||
| OKY-034 (Oral administration) |
LAT1
|
Pancreatic cancer
|
Low molecular
|
Japan
|
|
|||
| LAT1 inhibitor (In combination with other agents) |
LAT1
|
Biliary tract cancer/
pancreatic cancer |
Low molecular
|
Japan
|
|
|||
| LAT1 inhibitor |
LAT1
|
Autoimmune disease
|
Low molecular
|
US
|
|
|||
| NKO-028/035 (PET probe diagnostic) |
LAT1
|
Solid cancer
|
Diagnostic
|
Japan
|
＊＊＊
|
|||
* Ohara Pharmaceutical will file an application.
** A clinical trial is in preparation now.
*** Clinical research
** A clinical trial is in preparation now.
*** Clinical research